Fondaparinux

Human medicines European public assessment report (EPAR): Ondexxya, andexanet alfa, Date of authorisation: 26/04/2019, Revision: 17, Status: Authorised

Retrieved on: 
Tuesday, January 2, 2024
Patient, Medical Subject Headings, Marketing, Protein, Agency, INN, Fever, Risk, IIA, Allergy, ATC, Destiny of X, Fondaparinux, Blood, Bleeding, International, Ageing, Language, Thrombosis, Stroke, European Medicines Agency, Anticoagulant, Select, Side effect, Anatomy, Rivaroxaban

Human medicines European public assessment report (EPAR): Ondexxya, andexanet alfa, Date of authorisation: 26/04/2019, Revision: 17, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Ondexxya, andexanet alfa, Date of authorisation: 26/04/2019, Revision: 17, Status: Authorised

ALX Oncology Appoints Scott Garland to its Board of Directors

Retrieved on: 
Tuesday, November 29, 2022
Medullary thyroid cancer, SAN, Fondaparinux, Chief commercial officer, Triple accreditation, Alexion, Biotechnology, Therapy, Patient, CD47, Hyperkalemia, Lymphatic system, Security (finance), ALX, FC, Cancer, Research, Duke University, Genentech, California Polytechnic State University, Fuqua School, Bachelor of Science in Nursing, Business, Pharmaceutical industry, Portola Pharmaceuticals, Exelixis

SOUTH SAN FRANCISCO, Calif., Nov. 29, 2022 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (ALX Oncology) (Nasdaq: ALXO) a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, today announced the appointment of Scott Garland to its Board of Directors (the Board) effective November 29, 2022.

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., Nov. 29, 2022 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (ALX Oncology) (Nasdaq: ALXO) a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, today announced the appointment of Scott Garland to its Board of Directors (the Board) effective November 29, 2022.
  • Scott is a biopharmaceutical industry leader who brings broad commercial, portfolio management, and leadership experience to the Board, said Corey Goodman, Ph.D., Executive Chairman of ALX Oncology.
  • On behalf of the Board and our executive leadership team, we welcome Scott and look forward to his contributions.
  • Mr. Garland sits on the Board for Day One Biopharmaceuticals and Calithera Biosciences, and formerly sat on the Board of Karyopharm Therapeutics.

Octapharma shares new data at ISTH 2022 in its mission to meet the challenges faced by people with bleeding disorders

Retrieved on: 
Monday, July 4, 2022
Efficacy, Von Willebrand disease, Product, Critical care, Head, DDAVP, Patient, Atomic mass, III, VWF, Adult, International Society on Thrombosis and Haemostasis, Factor VIII, Pharmacokinetics, Spotlight, Female, Gold, VIII, Plasma, Thrombosis, Awareness, Woman, Risk, Bleeding, Pensioner, BST, Immunotherapy, Haemophilia, RNA, Fondaparinux, Quality of life, Coagulopathy, VWD, PTP, Congress, Epitope, International Society, ISTH, Dietary supplement, Vaccine, Pharmaceutical industry, Birth control, Bookkeeping, Factor VIII (medication), Octapharma, Symposia, Safety

The data will be featured in eleven poster presentations and two Supported Symposia during this major international meeting.

Key Points: 
  • The data will be featured in eleven poster presentations and two Supported Symposia during this major international meeting.
  • Octapharma is proud to be a Gold Supporter of the ISTH 2022 Congress.
  • Safety and pharmacokinetics of a subcutaneous recombinant FVIII (OCTA101) in adult patients with severe haemophilia A. Presenting Author: Sigurd Knaub
    PB0559.
  • "Despite advances in the field, managing emergency bleeding and bleeding disorders still comes with considerable challenges.

Octapharma shares new data at ISTH 2022 in its mission to meet the challenges faced by people with bleeding disorders

Retrieved on: 
Monday, July 4, 2022
Efficacy, Von Willebrand disease, Product, Critical care, Head, DDAVP, Patient, Atomic mass, III, VWF, Adult, International Society on Thrombosis and Haemostasis, Factor VIII, Pharmacokinetics, Spotlight, Female, Gold, VIII, Plasma, Thrombosis, Awareness, Woman, Risk, Bleeding, Pensioner, BST, Immunotherapy, Haemophilia, RNA, Fondaparinux, Quality of life, Coagulopathy, VWD, PTP, Congress, Epitope, International Society, ISTH, Dietary supplement, Vaccine, Pharmaceutical industry, Birth control, Bookkeeping, Factor VIII (medication), Octapharma, Symposia, Safety

The data will be featured in eleven poster presentations and two Supported Symposia during this major international meeting.

Key Points: 
  • The data will be featured in eleven poster presentations and two Supported Symposia during this major international meeting.
  • Octapharma is proud to be a Gold Supporter of the ISTH 2022 Congress.
  • Safety and pharmacokinetics of a subcutaneous recombinant FVIII (OCTA101) in adult patients with severe haemophilia A. Presenting Author: Sigurd Knaub
    PB0559.
  • "Despite advances in the field, managing emergency bleeding and bleeding disorders still comes with considerable challenges.

HeartBeam Establishes Scientific Advisory Board and Appoints C. Michael Gibson, MD as Chairman

Retrieved on: 
Thursday, January 27, 2022
Health, Medical Devices, Technology, Telecommunications, Software, Cardiology, Hardware, Coronary artery disease, Coronavirus Scientific Advisory Board (Turkey), Risk, Board of directors, Result, Physician, Forward-looking statement, TIMI, Financial condition report, Cardiology, Board, Research, Prevalence, Thienopyridine, Medicine, Technology, Cardiovascular disease, Time, Leadership, Infarction, 3D, NASDAQ, Doctor of Philosophy, Twitter, Rivaroxaban, Arrhythmia, ECG, Patient, SAB, Thomson Reuters, Form, Director, Fondaparinux, MD, Founder, Â, MI, Analysis, Pharmaceutical industry, Medical device

In conjunction, world-renowned cardiologist C. Michael Gibson, MS, MD, was appointed as Chairman of the new SAB.

Key Points: 
  • In conjunction, world-renowned cardiologist C. Michael Gibson, MS, MD, was appointed as Chairman of the new SAB.
  • Dr. Gibson has been a leading investigator in trials of thrombolytic agents, glycoprotein 2b3a inhibitor agents, thienopyridines, factor Xa inhibitors, lipid-lowering agents and new devices.
  • Dr. Gibson was named one of the worlds most widely published and cited scientists of past decade in 2018 - 2021 by Thomson Reuters.
  • HeartBeam is initially focusing on a huge unmet need of helping diagnose heart attacks in patients outside of a medical institution.